Helius Medical Technologies (NASDAQ:HSDT) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Helius Medical Technologies (NASDAQ:HSDT) released its quarterly earnings data on Tuesday. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.09), Zacks reports. The business had revenue of $0.15 million during the quarter, compared to the consensus estimate of $0.10 million. Helius Medical Technologies had a negative return on equity of 244.82% and a negative net margin of 1,764.74%.

Helius Medical Technologies Stock Down 2.8 %

Shares of HSDT stock opened at $0.40 on Thursday. The company has a 50 day moving average price of $0.55 and a 200-day moving average price of $0.59. Helius Medical Technologies has a 52 week low of $0.37 and a 52 week high of $7.19. The firm has a market capitalization of $1.49 million, a PE ratio of -0.06 and a beta of 1.62.

Helius Medical Technologies Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.